nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—VDR—prostate cancer	0.329	0.778	CbGaD
Paricalcitol—CYP3A4—prostate cancer	0.0939	0.222	CbGaD
Paricalcitol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0486	0.207	CbGbCtD
Paricalcitol—CYP3A4—Bicalutamide—prostate cancer	0.0255	0.109	CbGbCtD
Paricalcitol—CYP3A4—Estramustine—prostate cancer	0.0237	0.101	CbGbCtD
Paricalcitol—CYP3A4—Abiraterone—prostate cancer	0.0211	0.09	CbGbCtD
Paricalcitol—CYP3A4—Flutamide—prostate cancer	0.0211	0.09	CbGbCtD
Paricalcitol—CYP3A4—Cabazitaxel—prostate cancer	0.0156	0.0666	CbGbCtD
Paricalcitol—CYP3A4—Estrone—prostate cancer	0.0153	0.0651	CbGbCtD
Paricalcitol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0136	0.058	CbGbCtD
Paricalcitol—CYP3A4—Conjugated Estrogens—prostate cancer	0.01	0.0426	CbGbCtD
Paricalcitol—CYP3A4—Mitoxantrone—prostate cancer	0.00909	0.0387	CbGbCtD
Paricalcitol—CYP3A4—Estradiol—prostate cancer	0.00878	0.0374	CbGbCtD
Paricalcitol—CYP3A4—Prednisone—prostate cancer	0.00755	0.0321	CbGbCtD
Paricalcitol—CYP3A4—Etoposide—prostate cancer	0.00573	0.0244	CbGbCtD
Paricalcitol—CYP3A4—Docetaxel—prostate cancer	0.00524	0.0223	CbGbCtD
Paricalcitol—CYP24A1—prostate gland—prostate cancer	0.00408	0.16	CbGeAlD
Paricalcitol—CYP3A4—Doxorubicin—prostate cancer	0.00391	0.0166	CbGbCtD
Paricalcitol—CYP24A1—seminal vesicle—prostate cancer	0.00345	0.135	CbGeAlD
Paricalcitol—UGT1A4—renal system—prostate cancer	0.00278	0.109	CbGeAlD
Paricalcitol—CYP24A1—renal system—prostate cancer	0.00278	0.109	CbGeAlD
Paricalcitol—VDR—prostate gland—prostate cancer	0.00225	0.0881	CbGeAlD
Paricalcitol—CYP3A4—urine—prostate cancer	0.00209	0.0821	CbGeAlD
Paricalcitol—VDR—epithelium—prostate cancer	0.00165	0.0648	CbGeAlD
Paricalcitol—VDR—renal system—prostate cancer	0.00153	0.0601	CbGeAlD
Paricalcitol—VDR—urethra—prostate cancer	0.0015	0.059	CbGeAlD
Paricalcitol—VDR—bone marrow—prostate cancer	0.00116	0.0454	CbGeAlD
Paricalcitol—VDR—testis—prostate cancer	0.00099	0.0388	CbGeAlD
Paricalcitol—Dihydrotachysterol—VDR—prostate cancer	0.000814	0.171	CrCbGaD
Paricalcitol—VDR—lymph node—prostate cancer	0.000718	0.0281	CbGeAlD
Paricalcitol—Calcipotriol—VDR—prostate cancer	0.000525	0.11	CrCbGaD
Paricalcitol—Alfacalcidol—VDR—prostate cancer	0.000525	0.11	CrCbGaD
Paricalcitol—Calcidiol—VDR—prostate cancer	0.000525	0.11	CrCbGaD
Paricalcitol—CYP3A4—renal system—prostate cancer	0.000512	0.0201	CbGeAlD
Paricalcitol—Calcitriol—VDR—prostate cancer	0.000468	0.0985	CrCbGaD
Paricalcitol—Calcipotriol—MPO—prostate cancer	0.000391	0.0823	CrCbGaD
Paricalcitol—Ergocalciferol—VDR—prostate cancer	0.000374	0.0787	CrCbGaD
Paricalcitol—Cholecalciferol—VDR—prostate cancer	0.000283	0.0597	CrCbGaD
Paricalcitol—Ergocalciferol—AR—prostate cancer	0.000271	0.0571	CrCbGaD
Paricalcitol—Calcitriol—CYP3A4—prostate cancer	0.000133	0.0281	CrCbGaD
Paricalcitol—Cholecalciferol—CYP2C19—prostate cancer	0.000127	0.0268	CrCbGaD
Paricalcitol—Cholecalciferol—CYP1A1—prostate cancer	0.000127	0.0267	CrCbGaD
Paricalcitol—Ergocalciferol—CYP3A4—prostate cancer	0.000107	0.0224	CrCbGaD
Paricalcitol—Cholecalciferol—CYP3A4—prostate cancer	8.08e-05	0.017	CrCbGaD
Paricalcitol—Connective tissue disorder—Epirubicin—prostate cancer	3.6e-05	0.000195	CcSEcCtD
Paricalcitol—Urethral disorder—Epirubicin—prostate cancer	3.59e-05	0.000195	CcSEcCtD
Paricalcitol—Loss of consciousness—Prednisone—prostate cancer	3.58e-05	0.000194	CcSEcCtD
Paricalcitol—Epistaxis—Doxorubicin—prostate cancer	3.56e-05	0.000193	CcSEcCtD
Paricalcitol—Anorexia—Capecitabine—prostate cancer	3.56e-05	0.000193	CcSEcCtD
Paricalcitol—Nausea—Estradiol—prostate cancer	3.56e-05	0.000193	CcSEcCtD
Paricalcitol—Vomiting—Mitoxantrone—prostate cancer	3.55e-05	0.000192	CcSEcCtD
Paricalcitol—Sinusitis—Doxorubicin—prostate cancer	3.54e-05	0.000192	CcSEcCtD
Paricalcitol—Hypertension—Prednisone—prostate cancer	3.52e-05	0.000191	CcSEcCtD
Paricalcitol—Rash—Mitoxantrone—prostate cancer	3.52e-05	0.000191	CcSEcCtD
Paricalcitol—Dermatitis—Mitoxantrone—prostate cancer	3.51e-05	0.000191	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.51e-05	0.00019	CcSEcCtD
Paricalcitol—Headache—Mitoxantrone—prostate cancer	3.49e-05	0.000189	CcSEcCtD
Paricalcitol—Hypotension—Capecitabine—prostate cancer	3.49e-05	0.000189	CcSEcCtD
Paricalcitol—Insomnia—Docetaxel—prostate cancer	3.49e-05	0.000189	CcSEcCtD
Paricalcitol—Arthralgia—Prednisone—prostate cancer	3.47e-05	0.000188	CcSEcCtD
Paricalcitol—Myalgia—Prednisone—prostate cancer	3.47e-05	0.000188	CcSEcCtD
Paricalcitol—Paraesthesia—Docetaxel—prostate cancer	3.46e-05	0.000188	CcSEcCtD
Paricalcitol—Anxiety—Prednisone—prostate cancer	3.46e-05	0.000187	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.44e-05	0.000187	CcSEcCtD
Paricalcitol—Dyspnoea—Docetaxel—prostate cancer	3.44e-05	0.000186	CcSEcCtD
Paricalcitol—Somnolence—Docetaxel—prostate cancer	3.43e-05	0.000186	CcSEcCtD
Paricalcitol—Discomfort—Prednisone—prostate cancer	3.43e-05	0.000186	CcSEcCtD
Paricalcitol—Eye disorder—Epirubicin—prostate cancer	3.42e-05	0.000185	CcSEcCtD
Paricalcitol—Hypersensitivity—Etoposide—prostate cancer	3.42e-05	0.000185	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.4e-05	0.000184	CcSEcCtD
Paricalcitol—Cardiac disorder—Epirubicin—prostate cancer	3.4e-05	0.000184	CcSEcCtD
Paricalcitol—Dyspepsia—Docetaxel—prostate cancer	3.39e-05	0.000184	CcSEcCtD
Paricalcitol—Insomnia—Capecitabine—prostate cancer	3.38e-05	0.000183	CcSEcCtD
Paricalcitol—Hypoaesthesia—Doxorubicin—prostate cancer	3.37e-05	0.000183	CcSEcCtD
Paricalcitol—Pharyngitis—Doxorubicin—prostate cancer	3.36e-05	0.000182	CcSEcCtD
Paricalcitol—Paraesthesia—Capecitabine—prostate cancer	3.35e-05	0.000182	CcSEcCtD
Paricalcitol—Decreased appetite—Docetaxel—prostate cancer	3.35e-05	0.000182	CcSEcCtD
Paricalcitol—Urinary tract disorder—Doxorubicin—prostate cancer	3.34e-05	0.000181	CcSEcCtD
Paricalcitol—Oedema peripheral—Doxorubicin—prostate cancer	3.34e-05	0.000181	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Docetaxel—prostate cancer	3.33e-05	0.00018	CcSEcCtD
Paricalcitol—Asthenia—Etoposide—prostate cancer	3.33e-05	0.00018	CcSEcCtD
Paricalcitol—Connective tissue disorder—Doxorubicin—prostate cancer	3.33e-05	0.00018	CcSEcCtD
Paricalcitol—Dyspnoea—Capecitabine—prostate cancer	3.33e-05	0.00018	CcSEcCtD
Paricalcitol—Oedema—Prednisone—prostate cancer	3.33e-05	0.00018	CcSEcCtD
Paricalcitol—Fatigue—Docetaxel—prostate cancer	3.32e-05	0.00018	CcSEcCtD
Paricalcitol—Angiopathy—Epirubicin—prostate cancer	3.32e-05	0.00018	CcSEcCtD
Paricalcitol—Urethral disorder—Doxorubicin—prostate cancer	3.32e-05	0.00018	CcSEcCtD
Paricalcitol—Nausea—Mitoxantrone—prostate cancer	3.31e-05	0.00018	CcSEcCtD
Paricalcitol—Immune system disorder—Epirubicin—prostate cancer	3.31e-05	0.000179	CcSEcCtD
Paricalcitol—Infection—Prednisone—prostate cancer	3.3e-05	0.000179	CcSEcCtD
Paricalcitol—Mediastinal disorder—Epirubicin—prostate cancer	3.3e-05	0.000179	CcSEcCtD
Paricalcitol—Constipation—Docetaxel—prostate cancer	3.3e-05	0.000179	CcSEcCtD
Paricalcitol—Pain—Docetaxel—prostate cancer	3.3e-05	0.000179	CcSEcCtD
Paricalcitol—Dyspepsia—Capecitabine—prostate cancer	3.29e-05	0.000178	CcSEcCtD
Paricalcitol—Chills—Epirubicin—prostate cancer	3.28e-05	0.000178	CcSEcCtD
Paricalcitol—Pruritus—Etoposide—prostate cancer	3.28e-05	0.000178	CcSEcCtD
Paricalcitol—Shock—Prednisone—prostate cancer	3.27e-05	0.000177	CcSEcCtD
Paricalcitol—Arrhythmia—Epirubicin—prostate cancer	3.27e-05	0.000177	CcSEcCtD
Paricalcitol—Nervous system disorder—Prednisone—prostate cancer	3.26e-05	0.000177	CcSEcCtD
Paricalcitol—Decreased appetite—Capecitabine—prostate cancer	3.25e-05	0.000176	CcSEcCtD
Paricalcitol—Alopecia—Epirubicin—prostate cancer	3.23e-05	0.000175	CcSEcCtD
Paricalcitol—Skin disorder—Prednisone—prostate cancer	3.23e-05	0.000175	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Capecitabine—prostate cancer	3.22e-05	0.000175	CcSEcCtD
Paricalcitol—Fatigue—Capecitabine—prostate cancer	3.22e-05	0.000175	CcSEcCtD
Paricalcitol—Hyperhidrosis—Prednisone—prostate cancer	3.21e-05	0.000174	CcSEcCtD
Paricalcitol—Mental disorder—Epirubicin—prostate cancer	3.21e-05	0.000174	CcSEcCtD
Paricalcitol—Pain—Capecitabine—prostate cancer	3.19e-05	0.000173	CcSEcCtD
Paricalcitol—Constipation—Capecitabine—prostate cancer	3.19e-05	0.000173	CcSEcCtD
Paricalcitol—Malnutrition—Epirubicin—prostate cancer	3.19e-05	0.000173	CcSEcCtD
Paricalcitol—Feeling abnormal—Docetaxel—prostate cancer	3.18e-05	0.000172	CcSEcCtD
Paricalcitol—Diarrhoea—Etoposide—prostate cancer	3.17e-05	0.000172	CcSEcCtD
Paricalcitol—Anorexia—Prednisone—prostate cancer	3.17e-05	0.000172	CcSEcCtD
Paricalcitol—Eye disorder—Doxorubicin—prostate cancer	3.17e-05	0.000172	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Docetaxel—prostate cancer	3.15e-05	0.000171	CcSEcCtD
Paricalcitol—Cardiac disorder—Doxorubicin—prostate cancer	3.14e-05	0.00017	CcSEcCtD
Paricalcitol—Tension—Epirubicin—prostate cancer	3.13e-05	0.00017	CcSEcCtD
Paricalcitol—Dysgeusia—Epirubicin—prostate cancer	3.12e-05	0.000169	CcSEcCtD
Paricalcitol—Nervousness—Epirubicin—prostate cancer	3.1e-05	0.000168	CcSEcCtD
Paricalcitol—Back pain—Epirubicin—prostate cancer	3.08e-05	0.000167	CcSEcCtD
Paricalcitol—Feeling abnormal—Capecitabine—prostate cancer	3.08e-05	0.000167	CcSEcCtD
Paricalcitol—Angiopathy—Doxorubicin—prostate cancer	3.07e-05	0.000167	CcSEcCtD
Paricalcitol—Dizziness—Etoposide—prostate cancer	3.07e-05	0.000166	CcSEcCtD
Paricalcitol—Muscle spasms—Epirubicin—prostate cancer	3.06e-05	0.000166	CcSEcCtD
Paricalcitol—Immune system disorder—Doxorubicin—prostate cancer	3.06e-05	0.000166	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Capecitabine—prostate cancer	3.05e-05	0.000166	CcSEcCtD
Paricalcitol—Mediastinal disorder—Doxorubicin—prostate cancer	3.05e-05	0.000166	CcSEcCtD
Paricalcitol—Abdominal pain—Docetaxel—prostate cancer	3.05e-05	0.000165	CcSEcCtD
Paricalcitol—Body temperature increased—Docetaxel—prostate cancer	3.05e-05	0.000165	CcSEcCtD
Paricalcitol—Chills—Doxorubicin—prostate cancer	3.04e-05	0.000165	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Prednisone—prostate cancer	3.03e-05	0.000164	CcSEcCtD
Paricalcitol—Arrhythmia—Doxorubicin—prostate cancer	3.03e-05	0.000164	CcSEcCtD
Paricalcitol—Insomnia—Prednisone—prostate cancer	3.01e-05	0.000163	CcSEcCtD
Paricalcitol—Alopecia—Doxorubicin—prostate cancer	2.99e-05	0.000162	CcSEcCtD
Paricalcitol—Paraesthesia—Prednisone—prostate cancer	2.99e-05	0.000162	CcSEcCtD
Paricalcitol—Mental disorder—Doxorubicin—prostate cancer	2.97e-05	0.000161	CcSEcCtD
Paricalcitol—Urticaria—Capecitabine—prostate cancer	2.97e-05	0.000161	CcSEcCtD
Paricalcitol—Ill-defined disorder—Epirubicin—prostate cancer	2.96e-05	0.00016	CcSEcCtD
Paricalcitol—Abdominal pain—Capecitabine—prostate cancer	2.95e-05	0.00016	CcSEcCtD
Paricalcitol—Body temperature increased—Capecitabine—prostate cancer	2.95e-05	0.00016	CcSEcCtD
Paricalcitol—Vomiting—Etoposide—prostate cancer	2.95e-05	0.00016	CcSEcCtD
Paricalcitol—Malnutrition—Doxorubicin—prostate cancer	2.95e-05	0.00016	CcSEcCtD
Paricalcitol—Anaemia—Epirubicin—prostate cancer	2.95e-05	0.00016	CcSEcCtD
Paricalcitol—Agitation—Epirubicin—prostate cancer	2.93e-05	0.000159	CcSEcCtD
Paricalcitol—Dyspepsia—Prednisone—prostate cancer	2.93e-05	0.000159	CcSEcCtD
Paricalcitol—Rash—Etoposide—prostate cancer	2.93e-05	0.000159	CcSEcCtD
Paricalcitol—Dermatitis—Etoposide—prostate cancer	2.92e-05	0.000158	CcSEcCtD
Paricalcitol—Headache—Etoposide—prostate cancer	2.91e-05	0.000158	CcSEcCtD
Paricalcitol—Tension—Doxorubicin—prostate cancer	2.89e-05	0.000157	CcSEcCtD
Paricalcitol—Decreased appetite—Prednisone—prostate cancer	2.89e-05	0.000157	CcSEcCtD
Paricalcitol—Dysgeusia—Doxorubicin—prostate cancer	2.89e-05	0.000157	CcSEcCtD
Paricalcitol—Malaise—Epirubicin—prostate cancer	2.87e-05	0.000156	CcSEcCtD
Paricalcitol—Fatigue—Prednisone—prostate cancer	2.87e-05	0.000155	CcSEcCtD
Paricalcitol—Nervousness—Doxorubicin—prostate cancer	2.86e-05	0.000155	CcSEcCtD
Paricalcitol—Vertigo—Epirubicin—prostate cancer	2.86e-05	0.000155	CcSEcCtD
Paricalcitol—Syncope—Epirubicin—prostate cancer	2.86e-05	0.000155	CcSEcCtD
Paricalcitol—Leukopenia—Epirubicin—prostate cancer	2.85e-05	0.000155	CcSEcCtD
Paricalcitol—Back pain—Doxorubicin—prostate cancer	2.85e-05	0.000155	CcSEcCtD
Paricalcitol—Constipation—Prednisone—prostate cancer	2.84e-05	0.000154	CcSEcCtD
Paricalcitol—Hypersensitivity—Docetaxel—prostate cancer	2.84e-05	0.000154	CcSEcCtD
Paricalcitol—Muscle spasms—Doxorubicin—prostate cancer	2.83e-05	0.000154	CcSEcCtD
Paricalcitol—Palpitations—Epirubicin—prostate cancer	2.82e-05	0.000153	CcSEcCtD
Paricalcitol—Loss of consciousness—Epirubicin—prostate cancer	2.8e-05	0.000152	CcSEcCtD
Paricalcitol—Cough—Epirubicin—prostate cancer	2.78e-05	0.000151	CcSEcCtD
Paricalcitol—Asthenia—Docetaxel—prostate cancer	2.77e-05	0.00015	CcSEcCtD
Paricalcitol—Nausea—Etoposide—prostate cancer	2.76e-05	0.000149	CcSEcCtD
Paricalcitol—Hypertension—Epirubicin—prostate cancer	2.75e-05	0.000149	CcSEcCtD
Paricalcitol—Hypersensitivity—Capecitabine—prostate cancer	2.75e-05	0.000149	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisone—prostate cancer	2.74e-05	0.000149	CcSEcCtD
Paricalcitol—Ill-defined disorder—Doxorubicin—prostate cancer	2.74e-05	0.000148	CcSEcCtD
Paricalcitol—Pruritus—Docetaxel—prostate cancer	2.73e-05	0.000148	CcSEcCtD
Paricalcitol—Anaemia—Doxorubicin—prostate cancer	2.73e-05	0.000148	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Prednisone—prostate cancer	2.72e-05	0.000147	CcSEcCtD
Paricalcitol—Myalgia—Epirubicin—prostate cancer	2.71e-05	0.000147	CcSEcCtD
Paricalcitol—Arthralgia—Epirubicin—prostate cancer	2.71e-05	0.000147	CcSEcCtD
Paricalcitol—Chest pain—Epirubicin—prostate cancer	2.71e-05	0.000147	CcSEcCtD
Paricalcitol—Agitation—Doxorubicin—prostate cancer	2.71e-05	0.000147	CcSEcCtD
Paricalcitol—Anxiety—Epirubicin—prostate cancer	2.7e-05	0.000147	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.69e-05	0.000146	CcSEcCtD
Paricalcitol—Discomfort—Epirubicin—prostate cancer	2.68e-05	0.000145	CcSEcCtD
Paricalcitol—Asthenia—Capecitabine—prostate cancer	2.68e-05	0.000145	CcSEcCtD
Paricalcitol—Malaise—Doxorubicin—prostate cancer	2.66e-05	0.000144	CcSEcCtD
Paricalcitol—Dry mouth—Epirubicin—prostate cancer	2.65e-05	0.000144	CcSEcCtD
Paricalcitol—Vertigo—Doxorubicin—prostate cancer	2.65e-05	0.000144	CcSEcCtD
Paricalcitol—Syncope—Doxorubicin—prostate cancer	2.64e-05	0.000143	CcSEcCtD
Paricalcitol—Urticaria—Prednisone—prostate cancer	2.64e-05	0.000143	CcSEcCtD
Paricalcitol—Pruritus—Capecitabine—prostate cancer	2.64e-05	0.000143	CcSEcCtD
Paricalcitol—Leukopenia—Doxorubicin—prostate cancer	2.64e-05	0.000143	CcSEcCtD
Paricalcitol—Diarrhoea—Docetaxel—prostate cancer	2.64e-05	0.000143	CcSEcCtD
Paricalcitol—Abdominal pain—Prednisone—prostate cancer	2.63e-05	0.000143	CcSEcCtD
Paricalcitol—Body temperature increased—Prednisone—prostate cancer	2.63e-05	0.000143	CcSEcCtD
Paricalcitol—Confusional state—Epirubicin—prostate cancer	2.62e-05	0.000142	CcSEcCtD
Paricalcitol—Palpitations—Doxorubicin—prostate cancer	2.61e-05	0.000141	CcSEcCtD
Paricalcitol—Oedema—Epirubicin—prostate cancer	2.6e-05	0.000141	CcSEcCtD
Paricalcitol—Loss of consciousness—Doxorubicin—prostate cancer	2.59e-05	0.000141	CcSEcCtD
Paricalcitol—Infection—Epirubicin—prostate cancer	2.58e-05	0.00014	CcSEcCtD
Paricalcitol—Cough—Doxorubicin—prostate cancer	2.57e-05	0.00014	CcSEcCtD
Paricalcitol—Shock—Epirubicin—prostate cancer	2.56e-05	0.000139	CcSEcCtD
Paricalcitol—Diarrhoea—Capecitabine—prostate cancer	2.55e-05	0.000138	CcSEcCtD
Paricalcitol—Nervous system disorder—Epirubicin—prostate cancer	2.55e-05	0.000138	CcSEcCtD
Paricalcitol—Dizziness—Docetaxel—prostate cancer	2.55e-05	0.000138	CcSEcCtD
Paricalcitol—Hypertension—Doxorubicin—prostate cancer	2.55e-05	0.000138	CcSEcCtD
Paricalcitol—Skin disorder—Epirubicin—prostate cancer	2.53e-05	0.000137	CcSEcCtD
Paricalcitol—Hyperhidrosis—Epirubicin—prostate cancer	2.51e-05	0.000136	CcSEcCtD
Paricalcitol—Arthralgia—Doxorubicin—prostate cancer	2.51e-05	0.000136	CcSEcCtD
Paricalcitol—Chest pain—Doxorubicin—prostate cancer	2.51e-05	0.000136	CcSEcCtD
Paricalcitol—Myalgia—Doxorubicin—prostate cancer	2.51e-05	0.000136	CcSEcCtD
Paricalcitol—Anxiety—Doxorubicin—prostate cancer	2.5e-05	0.000136	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.49e-05	0.000135	CcSEcCtD
Paricalcitol—Discomfort—Doxorubicin—prostate cancer	2.48e-05	0.000134	CcSEcCtD
Paricalcitol—Anorexia—Epirubicin—prostate cancer	2.48e-05	0.000134	CcSEcCtD
Paricalcitol—Dizziness—Capecitabine—prostate cancer	2.47e-05	0.000134	CcSEcCtD
Paricalcitol—Dry mouth—Doxorubicin—prostate cancer	2.46e-05	0.000133	CcSEcCtD
Paricalcitol—Vomiting—Docetaxel—prostate cancer	2.45e-05	0.000133	CcSEcCtD
Paricalcitol—Hypersensitivity—Prednisone—prostate cancer	2.45e-05	0.000133	CcSEcCtD
Paricalcitol—Rash—Docetaxel—prostate cancer	2.43e-05	0.000132	CcSEcCtD
Paricalcitol—Hypotension—Epirubicin—prostate cancer	2.43e-05	0.000132	CcSEcCtD
Paricalcitol—Dermatitis—Docetaxel—prostate cancer	2.43e-05	0.000132	CcSEcCtD
Paricalcitol—Confusional state—Doxorubicin—prostate cancer	2.43e-05	0.000132	CcSEcCtD
Paricalcitol—Headache—Docetaxel—prostate cancer	2.42e-05	0.000131	CcSEcCtD
Paricalcitol—Oedema—Doxorubicin—prostate cancer	2.41e-05	0.00013	CcSEcCtD
Paricalcitol—Infection—Doxorubicin—prostate cancer	2.39e-05	0.00013	CcSEcCtD
Paricalcitol—Asthenia—Prednisone—prostate cancer	2.39e-05	0.000129	CcSEcCtD
Paricalcitol—Vomiting—Capecitabine—prostate cancer	2.37e-05	0.000129	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.37e-05	0.000128	CcSEcCtD
Paricalcitol—Shock—Doxorubicin—prostate cancer	2.37e-05	0.000128	CcSEcCtD
Paricalcitol—Nervous system disorder—Doxorubicin—prostate cancer	2.36e-05	0.000128	CcSEcCtD
Paricalcitol—Rash—Capecitabine—prostate cancer	2.35e-05	0.000128	CcSEcCtD
Paricalcitol—Pruritus—Prednisone—prostate cancer	2.35e-05	0.000128	CcSEcCtD
Paricalcitol—Insomnia—Epirubicin—prostate cancer	2.35e-05	0.000128	CcSEcCtD
Paricalcitol—Dermatitis—Capecitabine—prostate cancer	2.35e-05	0.000128	CcSEcCtD
Paricalcitol—Headache—Capecitabine—prostate cancer	2.34e-05	0.000127	CcSEcCtD
Paricalcitol—Skin disorder—Doxorubicin—prostate cancer	2.34e-05	0.000127	CcSEcCtD
Paricalcitol—Paraesthesia—Epirubicin—prostate cancer	2.34e-05	0.000127	CcSEcCtD
Paricalcitol—Hyperhidrosis—Doxorubicin—prostate cancer	2.33e-05	0.000126	CcSEcCtD
Paricalcitol—Dyspnoea—Epirubicin—prostate cancer	2.32e-05	0.000126	CcSEcCtD
Paricalcitol—Somnolence—Epirubicin—prostate cancer	2.31e-05	0.000125	CcSEcCtD
Paricalcitol—Anorexia—Doxorubicin—prostate cancer	2.29e-05	0.000124	CcSEcCtD
Paricalcitol—Nausea—Docetaxel—prostate cancer	2.29e-05	0.000124	CcSEcCtD
Paricalcitol—Dyspepsia—Epirubicin—prostate cancer	2.29e-05	0.000124	CcSEcCtD
Paricalcitol—Diarrhoea—Prednisone—prostate cancer	2.28e-05	0.000123	CcSEcCtD
Paricalcitol—Decreased appetite—Epirubicin—prostate cancer	2.26e-05	0.000123	CcSEcCtD
Paricalcitol—Hypotension—Doxorubicin—prostate cancer	2.25e-05	0.000122	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Epirubicin—prostate cancer	2.25e-05	0.000122	CcSEcCtD
Paricalcitol—Fatigue—Epirubicin—prostate cancer	2.24e-05	0.000122	CcSEcCtD
Paricalcitol—Constipation—Epirubicin—prostate cancer	2.22e-05	0.000121	CcSEcCtD
Paricalcitol—Pain—Epirubicin—prostate cancer	2.22e-05	0.000121	CcSEcCtD
Paricalcitol—Nausea—Capecitabine—prostate cancer	2.22e-05	0.00012	CcSEcCtD
Paricalcitol—Dizziness—Prednisone—prostate cancer	2.2e-05	0.000119	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.19e-05	0.000119	CcSEcCtD
Paricalcitol—Insomnia—Doxorubicin—prostate cancer	2.18e-05	0.000118	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CYP2C18—prostate cancer	2.16e-05	0.00017	CbGpPWpGaD
Paricalcitol—Paraesthesia—Doxorubicin—prostate cancer	2.16e-05	0.000117	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.16e-05	0.00017	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—CREBBP—prostate cancer	2.15e-05	0.000169	CbGpPWpGaD
Paricalcitol—Dyspnoea—Doxorubicin—prostate cancer	2.15e-05	0.000116	CcSEcCtD
Paricalcitol—Feeling abnormal—Epirubicin—prostate cancer	2.14e-05	0.000116	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—GSTO1—prostate cancer	2.14e-05	0.000169	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—NAT2—prostate cancer	2.14e-05	0.000169	CbGpPWpGaD
Paricalcitol—Somnolence—Doxorubicin—prostate cancer	2.14e-05	0.000116	CcSEcCtD
Paricalcitol—VDR—Gene Expression—NCOA2—prostate cancer	2.13e-05	0.000167	CbGpPWpGaD
Paricalcitol—Gastrointestinal pain—Epirubicin—prostate cancer	2.13e-05	0.000115	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—P4HB—prostate cancer	2.12e-05	0.000167	CbGpPWpGaD
Paricalcitol—Dyspepsia—Doxorubicin—prostate cancer	2.12e-05	0.000115	CcSEcCtD
Paricalcitol—Vomiting—Prednisone—prostate cancer	2.11e-05	0.000115	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	2.11e-05	0.000166	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	2.11e-05	0.000166	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—AKR1C3—prostate cancer	2.11e-05	0.000166	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—EZH2—prostate cancer	2.1e-05	0.000165	CbGpPWpGaD
Paricalcitol—Rash—Prednisone—prostate cancer	2.1e-05	0.000114	CcSEcCtD
Paricalcitol—Dermatitis—Prednisone—prostate cancer	2.09e-05	0.000114	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PRKACB—prostate cancer	2.09e-05	0.000165	CbGpPWpGaD
Paricalcitol—Decreased appetite—Doxorubicin—prostate cancer	2.09e-05	0.000113	CcSEcCtD
Paricalcitol—Headache—Prednisone—prostate cancer	2.08e-05	0.000113	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.08e-05	0.000113	CcSEcCtD
Paricalcitol—Fatigue—Doxorubicin—prostate cancer	2.07e-05	0.000112	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP17A1—prostate cancer	2.07e-05	0.000163	CbGpPWpGaD
Paricalcitol—Urticaria—Epirubicin—prostate cancer	2.07e-05	0.000112	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SLC22A1—prostate cancer	2.06e-05	0.000162	CbGpPWpGaD
Paricalcitol—Pain—Doxorubicin—prostate cancer	2.06e-05	0.000112	CcSEcCtD
Paricalcitol—Constipation—Doxorubicin—prostate cancer	2.06e-05	0.000112	CcSEcCtD
Paricalcitol—Body temperature increased—Epirubicin—prostate cancer	2.06e-05	0.000111	CcSEcCtD
Paricalcitol—Abdominal pain—Epirubicin—prostate cancer	2.06e-05	0.000111	CcSEcCtD
Paricalcitol—VDR—Gene Expression—PARP1—prostate cancer	2.06e-05	0.000162	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	2.05e-05	0.000162	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.04e-05	0.000161	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	2.03e-05	0.000159	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—SERPINE1—prostate cancer	2.02e-05	0.000159	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SULT2A1—prostate cancer	2.01e-05	0.000158	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Doxorubicin—prostate cancer	1.98e-05	0.000108	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—MED12—prostate cancer	1.98e-05	0.000156	CbGpPWpGaD
Paricalcitol—Nausea—Prednisone—prostate cancer	1.98e-05	0.000107	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—NCOA2—prostate cancer	1.97e-05	0.000155	CbGpPWpGaD
Paricalcitol—Gastrointestinal pain—Doxorubicin—prostate cancer	1.97e-05	0.000107	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GNG5—prostate cancer	1.96e-05	0.000154	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—HSPA1A—prostate cancer	1.95e-05	0.000153	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ESR2—prostate cancer	1.95e-05	0.000153	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Epirubicin—prostate cancer	1.92e-05	0.000104	CcSEcCtD
Paricalcitol—Urticaria—Doxorubicin—prostate cancer	1.91e-05	0.000104	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	1.91e-05	0.00015	CbGpPWpGaD
Paricalcitol—Abdominal pain—Doxorubicin—prostate cancer	1.9e-05	0.000103	CcSEcCtD
Paricalcitol—Body temperature increased—Doxorubicin—prostate cancer	1.9e-05	0.000103	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—NCOA3—prostate cancer	1.89e-05	0.000149	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	1.89e-05	0.000149	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SLC5A5—prostate cancer	1.88e-05	0.000148	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	1.88e-05	0.000148	CbGpPWpGaD
Paricalcitol—Asthenia—Epirubicin—prostate cancer	1.87e-05	0.000101	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP2E1—prostate cancer	1.84e-05	0.000145	CbGpPWpGaD
Paricalcitol—Pruritus—Epirubicin—prostate cancer	1.84e-05	9.98e-05	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—NQO1—prostate cancer	1.82e-05	0.000143	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—HPGDS—prostate cancer	1.8e-05	0.000142	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	1.8e-05	0.000141	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NCOA1—prostate cancer	1.79e-05	0.000141	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—TH—prostate cancer	1.79e-05	0.000141	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP2C19—prostate cancer	1.79e-05	0.000141	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.78e-05	0.00014	CbGpPWpGaD
Paricalcitol—Diarrhoea—Epirubicin—prostate cancer	1.78e-05	9.65e-05	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	1.78e-05	0.00014	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP3A4—prostate cancer	1.77e-05	0.00014	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Doxorubicin—prostate cancer	1.77e-05	9.61e-05	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.77e-05	0.000139	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ACHE—prostate cancer	1.75e-05	0.000138	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTT1—prostate cancer	1.75e-05	0.000138	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP1B1—prostate cancer	1.74e-05	0.000137	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP2A6—prostate cancer	1.73e-05	0.000136	CbGpPWpGaD
Paricalcitol—Asthenia—Doxorubicin—prostate cancer	1.73e-05	9.36e-05	CcSEcCtD
Paricalcitol—Dizziness—Epirubicin—prostate cancer	1.72e-05	9.32e-05	CcSEcCtD
Paricalcitol—VDR—Gene Expression—AR—prostate cancer	1.72e-05	0.000135	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—HPGDS—prostate cancer	1.71e-05	0.000135	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—RXRA—prostate cancer	1.71e-05	0.000134	CbGpPWpGaD
Paricalcitol—Pruritus—Doxorubicin—prostate cancer	1.7e-05	9.23e-05	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	1.7e-05	0.000134	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GGT1—prostate cancer	1.69e-05	0.000133	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—AKR1C3—prostate cancer	1.68e-05	0.000132	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	1.68e-05	0.000132	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PRKACB—prostate cancer	1.67e-05	0.000132	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NCOA1—prostate cancer	1.66e-05	0.000131	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTT1—prostate cancer	1.66e-05	0.000131	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP17A1—prostate cancer	1.66e-05	0.00013	CbGpPWpGaD
Paricalcitol—Vomiting—Epirubicin—prostate cancer	1.65e-05	8.97e-05	CcSEcCtD
Paricalcitol—Diarrhoea—Doxorubicin—prostate cancer	1.65e-05	8.93e-05	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	1.64e-05	0.000129	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP19A1—prostate cancer	1.64e-05	0.000129	CbGpPWpGaD
Paricalcitol—Rash—Epirubicin—prostate cancer	1.64e-05	8.89e-05	CcSEcCtD
Paricalcitol—Dermatitis—Epirubicin—prostate cancer	1.64e-05	8.88e-05	CcSEcCtD
Paricalcitol—Headache—Epirubicin—prostate cancer	1.63e-05	8.83e-05	CcSEcCtD
Paricalcitol—Dizziness—Doxorubicin—prostate cancer	1.59e-05	8.63e-05	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—RXRA—prostate cancer	1.58e-05	0.000125	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NCOA2—prostate cancer	1.58e-05	0.000124	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	1.58e-05	0.000124	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	1.57e-05	0.000124	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SIRT1—prostate cancer	1.57e-05	0.000123	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	1.55e-05	0.000122	CbGpPWpGaD
Paricalcitol—Nausea—Epirubicin—prostate cancer	1.54e-05	8.38e-05	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.54e-05	0.000121	CbGpPWpGaD
Paricalcitol—Vomiting—Doxorubicin—prostate cancer	1.53e-05	8.3e-05	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—COMT—prostate cancer	1.52e-05	0.00012	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTP1—prostate cancer	1.52e-05	0.000119	CbGpPWpGaD
Paricalcitol—Rash—Doxorubicin—prostate cancer	1.52e-05	8.23e-05	CcSEcCtD
Paricalcitol—Dermatitis—Doxorubicin—prostate cancer	1.52e-05	8.22e-05	CcSEcCtD
Paricalcitol—Headache—Doxorubicin—prostate cancer	1.51e-05	8.17e-05	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SLC5A5—prostate cancer	1.51e-05	0.000118	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—NCOA2—prostate cancer	1.5e-05	0.000118	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ITPR1—prostate cancer	1.49e-05	0.000117	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP2E1—prostate cancer	1.47e-05	0.000116	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.47e-05	0.000116	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NQO1—prostate cancer	1.45e-05	0.000114	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—TH—prostate cancer	1.43e-05	0.000113	CbGpPWpGaD
Paricalcitol—Nausea—Doxorubicin—prostate cancer	1.43e-05	7.75e-05	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CYP3A4—prostate cancer	1.42e-05	0.000112	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ERCC2—prostate cancer	1.41e-05	0.000111	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—TYMS—prostate cancer	1.41e-05	0.000111	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	1.4e-05	0.00011	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP1B1—prostate cancer	1.39e-05	0.00011	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTM1—prostate cancer	1.39e-05	0.00011	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NR3C1—prostate cancer	1.39e-05	0.000109	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	1.38e-05	0.000108	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—LPL—prostate cancer	1.37e-05	0.000108	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GGT1—prostate cancer	1.35e-05	0.000106	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NCOA1—prostate cancer	1.33e-05	0.000105	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	1.32e-05	0.000104	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP1A1—prostate cancer	1.32e-05	0.000104	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ERCC2—prostate cancer	1.31e-05	0.000103	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP19A1—prostate cancer	1.31e-05	0.000103	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	1.31e-05	0.000103	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PPARA—prostate cancer	1.3e-05	0.000103	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GGT1—prostate cancer	1.28e-05	0.000101	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—prostate cancer	1.28e-05	0.0001	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—RXRA—prostate cancer	1.27e-05	9.96e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—NCOA1—prostate cancer	1.26e-05	9.93e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	1.24e-05	9.79e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—MTHFR—prostate cancer	1.23e-05	9.7e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	1.23e-05	9.66e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—COMT—prostate cancer	1.22e-05	9.59e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTP1—prostate cancer	1.21e-05	9.54e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PPARA—prostate cancer	1.21e-05	9.51e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—RXRA—prostate cancer	1.2e-05	9.45e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ITPR1—prostate cancer	1.19e-05	9.39e-05	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ESR1—prostate cancer	1.18e-05	9.29e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—COMT—prostate cancer	1.16e-05	9.1e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTP1—prostate cancer	1.15e-05	9.06e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	1.14e-05	8.98e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CAV1—prostate cancer	1.14e-05	8.94e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	1.14e-05	8.94e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—TYMS—prostate cancer	1.13e-05	8.87e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTM1—prostate cancer	1.11e-05	8.77e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—LPL—prostate cancer	1.09e-05	8.61e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.09e-05	8.54e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTM1—prostate cancer	1.06e-05	8.33e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP1A1—prostate cancer	1.06e-05	8.31e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ERCC2—prostate cancer	1.05e-05	8.25e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	1.04e-05	8.21e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CG—prostate cancer	1.04e-05	8.15e-05	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—CREBBP—prostate cancer	1.03e-05	8.14e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	1e-05	7.89e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HAO1—prostate cancer	9.9e-06	7.79e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	9.89e-06	7.78e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—MTHFR—prostate cancer	9.85e-06	7.75e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—INS—prostate cancer	9.8e-06	7.71e-05	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SERPINE1—prostate cancer	9.7e-06	7.63e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PPARA—prostate cancer	9.67e-06	7.6e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CREBBP—prostate cancer	9.6e-06	7.55e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CD—prostate cancer	9.1e-06	7.16e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CAV1—prostate cancer	9.09e-06	7.15e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NOS3—prostate cancer	8.6e-06	6.76e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CG—prostate cancer	8.28e-06	6.51e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CBR1—prostate cancer	8.07e-06	6.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ADI1—prostate cancer	8.07e-06	6.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PSAT1—prostate cancer	8.07e-06	6.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TST—prostate cancer	8.07e-06	6.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CSAD—prostate cancer	8.07e-06	6.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GRHL1—prostate cancer	8.07e-06	6.35e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CB—prostate cancer	7.93e-06	6.24e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—prostate cancer	7.86e-06	6.19e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—INS—prostate cancer	7.84e-06	6.16e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CREBBP—prostate cancer	7.67e-06	6.04e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—UGT2B15—prostate cancer	7.5e-06	5.9e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CKMT2—prostate cancer	7.5e-06	5.9e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—UGT2B17—prostate cancer	7.5e-06	5.9e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GRHPR—prostate cancer	7.5e-06	5.9e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CD—prostate cancer	7.28e-06	5.73e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SULT2B1—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NAGLU—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTM3—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AOX1—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RFK—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MBTPS1—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PGAM2—prostate cancer	7.05e-06	5.55e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NOS3—prostate cancer	6.87e-06	5.41e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTEN—prostate cancer	6.86e-06	5.39e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP3A43—prostate cancer	6.69e-06	5.26e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AMACR—prostate cancer	6.69e-06	5.26e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SRD5A2—prostate cancer	6.69e-06	5.26e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NAT1—prostate cancer	6.69e-06	5.26e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—DEGS1—prostate cancer	6.69e-06	5.26e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—EP300—prostate cancer	6.54e-06	5.14e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HSD17B1—prostate cancer	6.38e-06	5.02e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CB—prostate cancer	6.34e-06	4.99e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—prostate cancer	6.28e-06	4.94e-05	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—prostate cancer	6.14e-06	4.83e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—B4GALT4—prostate cancer	5.69e-06	4.47e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HPGD—prostate cancer	5.69e-06	4.47e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTEN—prostate cancer	5.48e-06	4.31e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TNFRSF21—prostate cancer	5.35e-06	4.21e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—EP300—prostate cancer	5.23e-06	4.11e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MTAP—prostate cancer	5.2e-06	4.09e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP7B1—prostate cancer	5.2e-06	4.09e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SULT1E1—prostate cancer	5.07e-06	3.99e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SRD5A1—prostate cancer	5.07e-06	3.99e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CA—prostate cancer	4.84e-06	3.81e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ACSL4—prostate cancer	4.83e-06	3.8e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HSD17B3—prostate cancer	4.83e-06	3.8e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PHGDH—prostate cancer	4.64e-06	3.65e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—UMPS—prostate cancer	4.64e-06	3.65e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ARG2—prostate cancer	4.64e-06	3.65e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—LDHB—prostate cancer	4.55e-06	3.58e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.46e-06	3.51e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—UCP3—prostate cancer	4.31e-06	3.39e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TCN2—prostate cancer	4.31e-06	3.39e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PDHA1—prostate cancer	4.31e-06	3.39e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTA3—prostate cancer	4.31e-06	3.39e-05	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—AKT1—prostate cancer	4.26e-06	3.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.11e-06	3.23e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.11e-06	3.23e-05	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—AKT1—prostate cancer	3.95e-06	3.11e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTA4—prostate cancer	3.94e-06	3.1e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.94e-06	3.1e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CA—prostate cancer	3.87e-06	3.04e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTA2—prostate cancer	3.84e-06	3.02e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ABCG5—prostate cancer	3.79e-06	2.98e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.79e-06	2.98e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTA1—prostate cancer	3.71e-06	2.92e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NAT2—prostate cancer	3.66e-06	2.88e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.66e-06	2.88e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTO1—prostate cancer	3.66e-06	2.88e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PLCB2—prostate cancer	3.51e-06	2.76e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—LRP2—prostate cancer	3.51e-06	2.76e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.51e-06	2.76e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—P4HB—prostate cancer	3.44e-06	2.71e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.35e-06	2.64e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.27e-06	2.57e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MED12—prostate cancer	3.21e-06	2.53e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GNG5—prostate cancer	3.19e-06	2.51e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—AKT1—prostate cancer	3.16e-06	2.49e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NCOA3—prostate cancer	3.07e-06	2.42e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HPGDS—prostate cancer	2.93e-06	2.3e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.91e-06	2.29e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ACHE—prostate cancer	2.84e-06	2.24e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTT1—prostate cancer	2.84e-06	2.24e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.81e-06	2.21e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.73e-06	2.15e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PRKACB—prostate cancer	2.72e-06	2.14e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.69e-06	2.12e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NCOA2—prostate cancer	2.56e-06	2.02e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.44e-06	1.92e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.39e-06	1.88e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NQO1—prostate cancer	2.36e-06	1.86e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TH—prostate cancer	2.33e-06	1.83e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.26e-06	1.78e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GGT1—prostate cancer	2.19e-06	1.72e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NCOA1—prostate cancer	2.16e-06	1.7e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RXRA—prostate cancer	2.05e-06	1.62e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—COMT—prostate cancer	1.98e-06	1.56e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTP1—prostate cancer	1.97e-06	1.55e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ITPR1—prostate cancer	1.94e-06	1.52e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TYMS—prostate cancer	1.83e-06	1.44e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTM1—prostate cancer	1.81e-06	1.42e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—LPL—prostate cancer	1.78e-06	1.4e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.72e-06	1.35e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ERCC2—prostate cancer	1.7e-06	1.34e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MTHFR—prostate cancer	1.6e-06	1.26e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PPARA—prostate cancer	1.57e-06	1.23e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CAV1—prostate cancer	1.48e-06	1.16e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.34e-06	1.06e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—INS—prostate cancer	1.27e-06	1e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CREBBP—prostate cancer	1.25e-06	9.8e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.18e-06	9.29e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NOS3—prostate cancer	1.12e-06	8.78e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.03e-06	8.1e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—prostate cancer	1.02e-06	8.03e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTEN—prostate cancer	8.9e-07	7e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—EP300—prostate cancer	8.49e-07	6.68e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.28e-07	4.94e-06	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKT1—prostate cancer	5.13e-07	4.03e-06	CbGpPWpGaD
